Zacks Research Research Analysts Raise Earnings Estimates for STERIS plc (NYSE:STE)

STERIS plc (NYSE:STE) – Analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of STERIS in a report released on Wednesday, September 25th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $8.87 for the year, up from their previous forecast of $8.85. The consensus estimate for STERIS’s current full-year earnings is $9.05 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.52 EPS, Q4 2026 earnings at $2.59 EPS, FY2026 earnings at $9.47 EPS and FY2027 earnings at $10.01 EPS.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the business posted $2.00 earnings per share.

Other equities analysts have also issued reports about the stock. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Thursday, August 8th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Finally, KeyCorp lifted their price target on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.00.

STERIS Stock Performance

STERIS stock opened at $239.05 on Monday. STERIS has a twelve month low of $195.47 and a twelve month high of $248.24. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $23.63 billion, a P/E ratio of 62.58 and a beta of 0.83. The stock’s 50 day moving average is $237.51 and its 200 day moving average is $225.71.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were given a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 0.95%. This is a positive change from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. STERIS’s payout ratio is presently 59.69%.

Insider Buying and Selling

In other STERIS news, Director Christopher S. Holland sold 473 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now directly owns 582 shares in the company, valued at $139,493.76. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On STERIS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA increased its holdings in shares of STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after purchasing an additional 778,613 shares during the period. Sustainable Growth Advisers LP raised its position in STERIS by 23.5% during the 1st quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock worth $333,988,000 after buying an additional 282,387 shares during the last quarter. Impax Asset Management Group plc lifted its stake in STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after acquiring an additional 263,383 shares during the period. American Century Companies Inc. boosted its holdings in shares of STERIS by 1,946.3% in the 2nd quarter. American Century Companies Inc. now owns 270,311 shares of the medical equipment provider’s stock valued at $59,344,000 after acquiring an additional 257,101 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of STERIS by 71.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 603,879 shares of the medical equipment provider’s stock worth $132,763,000 after acquiring an additional 252,200 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.